SI1496917T1 - Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj - Google Patents
Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenjInfo
- Publication number
- SI1496917T1 SI1496917T1 SI200330173T SI200330173T SI1496917T1 SI 1496917 T1 SI1496917 T1 SI 1496917T1 SI 200330173 T SI200330173 T SI 200330173T SI 200330173 T SI200330173 T SI 200330173T SI 1496917 T1 SI1496917 T1 SI 1496917T1
- Authority
- SI
- Slovenia
- Prior art keywords
- beta
- treatment
- aminosugars
- combination
- adrenoceptor agonists
- Prior art date
Links
- 150000002337 glycosamines Chemical class 0.000 title abstract 3
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 title abstract 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 230000009610 hypersensitivity Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 150000002771 monosaccharide derivatives Chemical group 0.000 abstract 1
- 229960002052 salbutamol Drugs 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37361502P | 2002-04-19 | 2002-04-19 | |
| DKPA200200586 | 2002-04-19 | ||
| EP03752710A EP1496917B1 (en) | 2002-04-19 | 2003-04-22 | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| PCT/DK2003/000263 WO2003097073A1 (en) | 2002-04-19 | 2003-04-22 | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1496917T1 true SI1496917T1 (sl) | 2006-06-30 |
Family
ID=49447268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200330173T SI1496917T1 (sl) | 2002-04-19 | 2003-04-22 | Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050130935A1 (sl) |
| EP (2) | EP1496917B1 (sl) |
| JP (1) | JP2005529151A (sl) |
| KR (1) | KR20050007460A (sl) |
| CN (1) | CN1646143A (sl) |
| AT (1) | ATE311889T1 (sl) |
| AU (1) | AU2003260279B2 (sl) |
| CA (1) | CA2482746A1 (sl) |
| DE (1) | DE60308915T2 (sl) |
| DK (1) | DK1496917T3 (sl) |
| EA (1) | EA007906B1 (sl) |
| ES (1) | ES2254960T3 (sl) |
| NO (1) | NO20045038L (sl) |
| NZ (1) | NZ536447A (sl) |
| PL (1) | PL373190A1 (sl) |
| SI (1) | SI1496917T1 (sl) |
| WO (1) | WO2003097073A1 (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2499170A1 (en) | 2002-09-27 | 2004-04-08 | Children's Medical Center Corporation | Methods and compositions for treatment of neurological disorder |
| CA2558126A1 (en) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
| MX2007012794A (es) * | 2005-04-13 | 2008-02-22 | Astion Pharma As | Composiciones para el tratamiento de trastornos del tejido conectivo de la piel. |
| US20160045457A1 (en) | 2005-09-09 | 2016-02-18 | Ousama Rachid | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine |
| US20070059361A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
| WO2007143676A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| US20070293581A1 (en) * | 2006-06-05 | 2007-12-20 | Malcolm Hill | Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies |
| GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
| EP2155207A2 (en) * | 2007-05-31 | 2010-02-24 | Government Of The United States Of America As Represented by Secretary of the Dep. of Health and Human Services National Institute of Health | N-acetyl mannosamine as a therapeutic agent |
| GB0805535D0 (en) | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
| US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20120322884A1 (en) | 2010-03-01 | 2012-12-20 | University Of Manitoba | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| WO2011126910A2 (en) | 2010-03-30 | 2011-10-13 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
| US8716350B2 (en) | 2010-03-30 | 2014-05-06 | Algynomics Inc. | Compositions and methods for the treatment of somatosensory disorders |
| CA2853084C (en) | 2011-10-21 | 2022-04-26 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| EP2861224A4 (en) | 2012-06-15 | 2015-11-18 | Univ Nova Southeastern | EPINEPHRINNANOPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF FOR TREATING SUFFERING SUFFERING TO EPINEPHRIN |
| GB2513297A (en) | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
| HRP20211286T1 (hr) | 2013-03-22 | 2021-12-24 | Nova Southeastern University | Fine čestice epinefrina i metode njihove korištenja za liječenje stanja koja odgovaraju na epinefrin |
| CN105601685B (zh) * | 2016-01-08 | 2017-12-26 | 鲁东大学 | 含喹唑啉环壳寡糖衍生物及制备方法和生物活性 |
| WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
| JP7657457B2 (ja) | 2018-10-19 | 2025-04-07 | ノバ サウスイースタン ユニバーシティー | ｐＨ修飾賦形剤及び浸入促進剤を含む舌下エピネフリン組成物及びそれを使用する方法 |
| CA3195941A1 (en) * | 2020-10-20 | 2022-04-28 | Napoleone Ferrara | Compositions and methods for treating ischemic conditions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| JP3390477B2 (ja) * | 1993-01-25 | 2003-03-24 | 生化学工業株式会社 | 薬剤組成物及びその製造法 |
| WO1995019336A1 (de) * | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten |
| US6255295B1 (en) * | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
| US6046179A (en) * | 1998-04-17 | 2000-04-04 | Murch; Simon | Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine |
| US20020136782A1 (en) * | 2001-01-18 | 2002-09-26 | Fleischner Albert M. | Composition patent for solid-dosage form of weight loss product |
| US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
-
2003
- 2003-04-22 DE DE60308915T patent/DE60308915T2/de not_active Expired - Fee Related
- 2003-04-22 SI SI200330173T patent/SI1496917T1/sl unknown
- 2003-04-22 DK DK03752710T patent/DK1496917T3/da active
- 2003-04-22 PL PL03373190A patent/PL373190A1/xx not_active Application Discontinuation
- 2003-04-22 AU AU2003260279A patent/AU2003260279B2/en not_active Expired - Fee Related
- 2003-04-22 CA CA002482746A patent/CA2482746A1/en not_active Abandoned
- 2003-04-22 NZ NZ536447A patent/NZ536447A/en unknown
- 2003-04-22 CN CNA038087146A patent/CN1646143A/zh active Pending
- 2003-04-22 KR KR10-2004-7016710A patent/KR20050007460A/ko not_active Withdrawn
- 2003-04-22 ES ES03752710T patent/ES2254960T3/es not_active Expired - Lifetime
- 2003-04-22 JP JP2004505071A patent/JP2005529151A/ja active Pending
- 2003-04-22 EA EA200401404A patent/EA007906B1/ru not_active IP Right Cessation
- 2003-04-22 AT AT03752710T patent/ATE311889T1/de not_active IP Right Cessation
- 2003-04-22 WO PCT/DK2003/000263 patent/WO2003097073A1/en active IP Right Grant
- 2003-04-22 EP EP03752710A patent/EP1496917B1/en not_active Expired - Lifetime
- 2003-04-22 US US10/512,029 patent/US20050130935A1/en not_active Abandoned
- 2003-04-22 EP EP05013726A patent/EP1642574A3/en not_active Withdrawn
-
2004
- 2004-11-19 NO NO20045038A patent/NO20045038L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE311889T1 (de) | 2005-12-15 |
| EP1496917A1 (en) | 2005-01-19 |
| NO20045038L (no) | 2004-11-19 |
| EP1642574A2 (en) | 2006-04-05 |
| NZ536447A (en) | 2006-05-26 |
| JP2005529151A (ja) | 2005-09-29 |
| KR20050007460A (ko) | 2005-01-18 |
| AU2003260279A1 (en) | 2003-12-02 |
| EA200401404A1 (ru) | 2005-04-28 |
| AU2003260279B2 (en) | 2008-01-24 |
| HK1073436A1 (en) | 2005-10-07 |
| DE60308915T2 (de) | 2006-12-21 |
| EP1642574A3 (en) | 2008-11-12 |
| PL373190A1 (en) | 2005-08-22 |
| ES2254960T3 (es) | 2006-06-16 |
| US20050130935A1 (en) | 2005-06-16 |
| EA007906B1 (ru) | 2007-02-27 |
| CN1646143A (zh) | 2005-07-27 |
| WO2003097073A1 (en) | 2003-11-27 |
| CA2482746A1 (en) | 2003-11-27 |
| DK1496917T3 (da) | 2006-04-10 |
| EP1496917B1 (en) | 2005-12-07 |
| DE60308915D1 (de) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1496917T1 (sl) | Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj | |
| WO2007014334A3 (en) | Method of treatment or management of stress | |
| IL267381A (en) | A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders | |
| MX2007012794A (es) | Composiciones para el tratamiento de trastornos del tejido conectivo de la piel. | |
| DE60124715D1 (de) | Er produktion von beta-endorphin | |
| CA2420895A1 (en) | Method for treating erectile dysfunction and increasing libido in men | |
| CA2353553A1 (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| WO2004091521A3 (en) | Methods and compositions for administration of trpv1 agonists | |
| AR041725A1 (es) | Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica | |
| WO2004004661A3 (en) | Boroproline compound combination therapy | |
| CO5601022A2 (es) | Metodos para tratar pacientes que padecen transtornos de movimiento | |
| EP1157698A3 (en) | Treatment of inflammatory diseases with oxypurine nucleosides | |
| CA2407008A1 (en) | Medicated wrap | |
| WO2003007876A3 (en) | N-fatty acid-amino acid conjugates and therapeutic uses | |
| WO2004031144A3 (en) | Use of caspase inhibitors as therapeutic agent against radiation-induced injury | |
| AU2003290970A1 (en) | Compositions and method for treating affective, painful or allergic disorders | |
| WO2001045714A3 (en) | Formulations of adenosine a1 agonists | |
| PT1567140E (pt) | Combinação sinérgica compreendendo roflumilaste e (r,r)-formoterol | |
| TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
| AU2002357691A1 (en) | Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145 | |
| WO2004110416A3 (en) | Use of a cx3c agonist for the treatment of pain and for promoting nerve regeneration | |
| RU2003137519A (ru) | Иммуностимулирующее средство | |
| UA40154A (uk) | Спосіб визначення властивостей лікарського препарату |